Advanced search
Start date
Betweenand

Selective targeting of zinc finger domains with metallodrugs for therapy of parasitic diseases

Grant number: 18/21120-8
Support type:Regular Research Grants
Duration: June 01, 2019 - May 31, 2021
Field of knowledge:Physical Sciences and Mathematics - Chemistry - Inorganic Chemistry
Cooperation agreement: Cardiff University
Mobility Program: SPRINT - Projetos de pesquisa - Mobilidade
Principal Investigator:Camilla Abbehausen
Grantee:Camilla Abbehausen
Principal investigator abroad: Angela Casini
Institution abroad: Cardiff University, Wales
Home Institution: Instituto de Química (IQ). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil
Associated research grant:17/12719-0 - Fighting bacterial resistance: metal complexes and the metallo-beta-lactamases inhibition, AP.R

Abstract

In this project, several metal-based compounds will be systematically developed and evaluated to selectively target zinc finger domains (ZF). Based on the recent report that organometallic gold(III) cyclometalated compounds can selectively target PARP-1 ZF domains in a combination of Cys3His (PARP-1) with Cys2His2 (commonly found in transcription factor), we propose to rationalize the selectivity of metal-based compounds to develop novel drugs to target parasitic, specially Leishmania zinc finger domains. Also, X-ray absorption (XAS) studies have revealed the influences of the ligand and ZF type on the metal substitution reaction involved, elucidating mechanisms of the interaction of Au(I) and Au(III) compounds with NCp7 and with Sp1 ZF domains. This proposal supports a joint effort of the proponents to combine their expertise in the direction of developing selective anti-leishmaniasis drugs targeting zinc finger domains, offering less toxic drugs for these therapies. The work plan is summarized in some steps: (i) screen the compounds according to the anti-leishmaniasis activity in vitro (ii) evaluating the selectivity of Pt(II), Pd(II), Au(III), Au(I), Co(II) and Co(III) compounds by HPLC/MS in combination of viral/parasitic and human models; (iii) designing the modification to improve selectivity where needed; (iv) study the interaction by measuring the XAS spectra of the forming adducts. (AU)